Astellas Advances Alefacept To Phase II For Renal Transplant Rejection Prevention
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm will test the biologic as an adjunct to its immunosuppressant Prograf, which has a different mechanism of action.